Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says

Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet